References: 1. Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia. 2011;17:179-184. 2. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; November 2022. 3. Data on file. Chicago, IL: Medexus Pharma, Inc.

The information in this section is intended for healthcare providers in the United States. I certify that I am a healthcare provider in the United States.

Yes
No